E3A Healthcare took home 2nd place overall and Winner of the Health & Biomedical Domain at the 2022 SLINGSHOT Innovation Competition hosted by Enterprise Singapore.
The Global Finals of the SLINGSHOT 2022 Singapore International Innovation Competition was successfully concluded on October 27th at the Singapore Technology and Innovation Week.
E3A HEALTHCAREWON THE SECOND RUNNER-UP IN THE FINALS OF SLINGSHOT INTERNATIONAL INNOVATION COMPETITION IN SINGAPORE AND THE CHAMPION IN THE BIOMEDICAL GROUP WITH THE PROJECT OF SMART TRANSCUTANEOUS JAUNDICE INSTRUMENT FOR NEWBORNS.
The SLINGSHOT International Innovation Competition is organized by Startup SG and Enterprise Singapore (EnterpriseSG) to solicit innovative solutions from startups around the world.
THIS YEAR'S SLINGSHOT CONFERENCE ENCOMPASSES FIVE MAJOR CATEGORIES: HEALTH AND BIOMEDICINE; MANUFACTURING, TRADE AND CONNECTIVITY; ENVIRONMENT, ENERGY AND GREEN TECHNOLOGY; TRANSFORMATIVE DIGITAL TECHNOLOGY; AND CONSUMER MEDIA, GOODS AND SERVICES. THE CONFERENCE OFFERS OVER S$1.2 MILLION (US$800,000) IN TOTAL AWARDS TO THE WINNERS TO HELP GLOBAL STARTUPS REALIZE THEIR DREAMS.
E3A HEALTHCAREAS A PARTICIPANT OF THIS COMPETITION, DR. LI SHIHAO, THE FOUNDER CEO, ATTENDED THE COMPETITION AND INTRODUCED THE COMPANY'S PRODUCT DEVELOPMENT ACHIEVEMENTS AND DEVELOPMENT PLANS. E3A HEALTHCARETHROUGH SELF-DEVELOPED INNOVATIVE OPTICAL DETECTION PATENT TECHNOLOGY, THE NEW GENERATION OF NEWBORN INTELLIGENT TRANSCUTANEOUS JAUNDICE INSTRUMENT, A BREAKTHROUGH SOLUTION TO THE CURRENT GLOBAL MARKET FOR NEWBORN JAUNDICE CARE COMMONLY EXIST IN THE "DIFFICULT TO ACCESS, DIFFICULT TO USE, HIGH PRICES" AND OTHER USER PAIN POINTS.
With this product, we hope to improve the accessibility of neonatal jaundice care worldwide, reduce the health risks of neonatal jaundice, a disease that is highly prevalent in infants and children, and better protect new lives!
